$SAREPTA THERAPEUTICS INC(SRPT)$ Sarepta Therapeutics announces publication of Ebola and Marburg Phase I clinical study results in antimicrobial agents and chemotherapy; results show PMOplus drug candidates to be well-tolerated with no clinically significant effects on any evaluated safety parameters observed